0001567619-19-005678.txt : 20190228 0001567619-19-005678.hdr.sgml : 20190228 20190228193559 ACCESSION NUMBER: 0001567619-19-005678 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190226 FILED AS OF DATE: 20190228 DATE AS OF CHANGE: 20190228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kramer Robert CENTRAL INDEX KEY: 0001380956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 19646133 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc1.xml FORM 4 X0306 4 2019-02-26 0 0001367644 Emergent BioSolutions Inc. EBS 0001380956 Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 0 1 0 0 President and COO Common Stock 2019-02-26 4 F 0 565 61.01 D 90607 D Common Stock 2019-02-26 4 A 0 11801 0.00 A 102408 D Common Stock 2019-02-26 4 A 0 11801 0.00 A 114209 D Common Stock 2019-02-27 4 F 0 779 57.98 D 113430 D Common Stock 2019-02-28 4 F 0 1941 58.71 D 111489 D Employee Stock Option (Right to Buy) 61.01 2019-02-26 4 A 0 47197 61.01 A 2026-02-25 Common Stock 47197 47197 D Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Vests in three equal installments beginning on the day prior to the anniversary date of the grant. /s/ S. Scott Lieberman, Attorney-in-fact 2019-02-28